Invitae Files Suit Against Myriad Genetics

  Invitae Files Suit Against Myriad Genetics

Business Wire

SAN FRANCISCO -- December 2, 2013

Invitae Corporation, a genetic diagnostics company, today announced that it
filed an action in the U.S. District Court for the Northern District of
California against Myriad Genetics, Inc. (NASDAQ: MYGN). By its suit, Invitae
seeks a declaration that certain Myriad patents relating to the BRCA1/2 and
MUTYH genes are invalid and are not infringed by Invitae.

Invitae’s announcement today reinforces its commitment to defend its right to
provide naturally occurring genetic information and services to physicians for
their cancer patients (see Invitae Responds to Myriad Genetics Lawsuit).
Earlier this year, the Supreme Court ruled that naturally occurring DNA and
the information it encodes cannot be patented (Assn’n for Molecular Pathology
v. Myriad Genetics, Inc., 133 S. Ct. 2107 [2013]) and thus ushered in a new
era of personalized medicine. Moreover, the Supreme Court’s June decision
followed its prior ruling establishing that naturally occurring biological
correlations were not patentable subject matter (Mayo Collaborative Servs. v.
Prometheus Labs., Inc., 132 S. Ct. 1289 [2011]).

“We believe the Supreme Court rulings validate Invitae’s view that no company
can claim ownership over naturally occurring genetic information,” said Randy
Scott, co-founder of Invitae. “Our suit is based on the teachings of these
cases. The legal process will take its course, and we are steadfast in our
resolve.”

About Invitae Corporation

Specializing in genetic diagnostics for hereditary disorders, Invitae’s
mission is to make multi-use genetic testing more accessible and affordable
than ever before.

The company is pursuing a strategy over the next several years to aggregate
all the world's medical genetic tests (>3,000 known Mendelian conditions) into
a single assay at a lower cost than most single gene tests today.

This capability is increasingly enabled by the rapid advancements in DNA
sequencing technology. Invitae hopes to lead the way from an era of genetic
scarcity to genetic abundance to significantly improve healthcare worldwide.

For further information, please visit www.invitae.com.

Contact:

Invitae Corporation
Katherine Stueland, 206-226-0672
pr@invitae.com
or
BrewLife
Paul Laland, 415-946-1071
plaland@brewlife.com
 
Press spacebar to pause and continue. Press esc to stop.